144 related articles for article (PubMed ID: 15197773)
21. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
[TBL] [Abstract][Full Text] [Related]
22. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.
Spinola M; Leoni VP; Tanuma J; Pettinicchio A; Frattini M; Signoroni S; Agresti R; Giovanazzi R; Pilotti S; Bertario L; Ravagnani F; Dragani TA
Oncol Rep; 2005 Aug; 14(2):415-9. PubMed ID: 16012724
[TBL] [Abstract][Full Text] [Related]
23. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
25. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.
Morimoto Y; Ozaki T; Ouchida M; Umehara N; Ohata N; Yoshida A; Shimizu K; Inoue H
Cancer; 2003 Nov; 98(10):2245-50. PubMed ID: 14601095
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
27. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
28. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
29. Association of -308 TNF-α promoter polymorphism with clinical aggressiveness in patients with head and neck squamous cell carcinoma.
Corrêa GT; Bandeira GA; Cavalcanti BG; de Carvalho Fraga CA; dos Santos EP; Silva TF; Gomez RS; Guimarães AL; De Paula AM
Oral Oncol; 2011 Sep; 47(9):888-94. PubMed ID: 21788151
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome.
de Koning PJ; Bovenschen N; Leusink FK; Broekhuizen R; Quadir R; van Gemert JT; Hordijk GJ; Chang WS; van der Tweel I; Tilanus MG; Kummer JA
Int J Cancer; 2009 Oct; 125(7):1542-50. PubMed ID: 19569240
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
[TBL] [Abstract][Full Text] [Related]
32. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients.
Choi CH; Chung JY; Kim JH; Kim BG; Hewitt SM
J Transl Med; 2016 May; 14(1):124. PubMed ID: 27154171
[TBL] [Abstract][Full Text] [Related]
33. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors.
Lima LM; de Souza LR; da Silva TF; Pereira CS; Guimarães AL; de Paula AM; de Andrade Carvalho H
Histopathology; 2012 Feb; 60(3):489-96. PubMed ID: 22176134
[TBL] [Abstract][Full Text] [Related]
34. Is FGFR4 Gly388Arg missense variant a suitable prognostic marker in neuroblastoma?
Katarzyna S
J Cancer Res Ther; 2023; 19(2):355-358. PubMed ID: 37006072
[TBL] [Abstract][Full Text] [Related]
35. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome.
Brito LP; Lerário AM; Bronstein MD; Soares IC; Mendonca BB; Fragoso MC
J Clin Endocrinol Metab; 2010 Oct; 95(10):E271-9. PubMed ID: 20660043
[TBL] [Abstract][Full Text] [Related]
36. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
Marmé F; Werft W; Benner A; Burwinkel B; Sinn P; Sohn C; Lichter P; Hahn M; Schneeweiss A
Ann Oncol; 2010 Aug; 21(8):1636-1642. PubMed ID: 20147743
[TBL] [Abstract][Full Text] [Related]
37. The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients.
Ye YW; Zhang X; Zhou Y; Wu J; Zhao C; Yuan L; Wang G; Du C; Wang C; Shi Y
J Surg Oncol; 2012 Dec; 106(7):872-9. PubMed ID: 22585711
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
39. Gender-Specific Association Between FGFR4 Gly388Arg Gene Variants and Hypertension.
Al-Daghri NM; Mohammed AK; Al-Attas OS; Draz HM; Alokail MS
Genet Test Mol Biomarkers; 2017 Jul; 21(7):422-427. PubMed ID: 28650667
[TBL] [Abstract][Full Text] [Related]
40. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas.
Cortezzi SS; Provazzi PJ; Sobrinho JS; Mann-Prado JC; Reis PM; de Freitas SE; Filho JF; Fukuyama EE; Cordeiro JA; Cury PM; Maniglia JV; Villa LL; Tajara EH; Rahal P
Cancer Genet Cytogenet; 2004 Apr; 150(1):44-9. PubMed ID: 15041222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
